SNQM Up 38% or $3.51 Since 6/4

Sequenom Inc (NasdaqGM: SQNM) shares continue to surge on news that the company's core product could soon become the standard process in the $1billion Down syndrome testing market.

The Street appears pretty confident that SQNM has an ace in the hole here with its Down's test.

Oppenheimer and Co. analyst Kevin DeGeeter recently set a 17.50 price target on the stock and he could be right on if momentum continues to build.